STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer properties. It works by blocking the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites, significantly reducing the expression of the STAT5B protein. This leads to the inhibition of downstream gene transcription, thereby preventing the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 has significant potential in overcoming chemotherapy resistance.

STAT5-IN-3 (Compound 14a) (100 nM-10 μM; 48 h) 可以有效抑制髓系白血病细胞 (KU812, K562, KCL-22, MV-4-11 和 MOLM-13) 的活性，EC50 分别为 0.6 μM、0.8 μM、0.5 μM、0.3 μM 和 0.3 μM，同时对正常细胞 (HS27A 和 MSC) 显示出较低的毒性，其 EC50 都大于 10 μM [1]。